[Featured Stock] Paksel Bio Surges for Second Day on Anticancer Drug Approval Hopes
[Asia Economy Reporter Park Ji-hwan] The stock price of Baxel Bio is soaring day by day.
According to the Korea Exchange on the 25th, as of 9:16 a.m., Baxel Bio is trading at 138,100 KRW, up 15.18% from the previous trading day. Baxel Bio also closed at the upper limit the day before. This marks a continuous surge for the past three trading days including today.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
It is interpreted that investor sentiment was stimulated as the government approval deadline for Baxlukin, an anticancer immunotherapy drug exclusively for companion dogs developed by Baxel Bio, is approaching. Baxel Bio is a company that researches and develops anticancer immunotherapy drugs.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
